Jane Street Group LLC Raises Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Jane Street Group LLC lifted its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 26.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 385,594 shares of the company's stock after buying an additional 79,942 shares during the quarter. Jane Street Group LLC owned about 0.26% of MiMedx Group worth $3,709,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of MDXG. First Light Asset Management LLC purchased a new stake in MiMedx Group in the fourth quarter worth about $32,168,000. Norges Bank bought a new stake in shares of MiMedx Group in the 4th quarter worth approximately $4,020,000. JPMorgan Chase & Co. grew its stake in shares of MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after buying an additional 395,739 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in MiMedx Group by 484.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock valued at $3,487,000 after buying an additional 300,433 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in MiMedx Group by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after buying an additional 280,327 shares in the last quarter. 79.15% of the stock is owned by institutional investors.

MiMedx Group Stock Down 0.6%

Shares of MDXG traded down $0.04 on Friday, hitting $7.05. 614,522 shares of the stock traded hands, compared to its average volume of 693,084. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a market capitalization of $1.04 billion, a PE ratio of 12.82 and a beta of 1.85. The business has a 50 day simple moving average of $7.21 and a 200 day simple moving average of $8.15. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. As a group, equities analysts forecast that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on MDXG shares. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. StockNews.com cut shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 9th.

Insiders Place Their Bets

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joseph H. Capper purchased 200,000 shares of the business's stock in a transaction on Friday, May 2nd. The shares were purchased at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the purchase, the chief executive officer now owns 529,530 shares in the company, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 144,018 shares of company stock valued at $1,130,312. 1.70% of the stock is owned by insiders.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.